Hepatitis Vaccine

Enrollment complete for phase II/III hepatitis B prophylactic vaccine trial

Published in Hepatitis Weekly, September 27th, 2004

Dynavax Technologies Corp. (DVAX), has completed enrollment and administered the first round of immunizations in a phase II/III clinical trial of its hepatitis B (HBV) prophylactic vaccine candidate containing Dynavax's Immunostimulatory Sequence.

The study, being conducted at two study centers in Singapore, began enrollment in June 2004.

The double-blind study compares Dynavax's HBV vaccine candidate with GlaxoSmithKline's marketed HBV vaccine, Engerix-B, in 94 subjects. The subjects, ranging between 40-70 years of age, had not previously been immunized against HBV. The full immunization schedule will consist of three injections over 6 months, with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry